YL217
/ MediLink
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 11, 2025
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=220 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Solid Tumor
July 03, 2025
Yilian Biopharmaceuticals' YL217 project completes first patient dosing [Google translation]
(Yilian Biopharma Press Release)
- "Suzhou Yilian Biopharmaceutical Co., Ltd...announced that its independently developed antibody-drug conjugate YL217 successfully completed the first dosing of the first subject in the global Phase I clinical trial in China."
Trial status • Oncology • Solid Tumor
March 26, 2025
Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors
(AACR 2025)
- "Moreover, acceptable safety profiles were also noted in monkey GLP toxicity studies. Taken together, preclinical data suggest that YL217 could be further developed in the treatment of CDH17-positive cancer patients."
Preclinical • Oncology • Solid Tumor • CDH17
March 05, 2025
A First-in-Human Study of YL217 in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=220 | Not yet recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
New P1 trial • Oncology • Solid Tumor
February 02, 2025
Yilian Biopharmaceuticals’ YL217 project received FDA approval for clinical trials [Google translation]
(Yilian Biotech Press Release)
- "Suzhou Yilian Biopharmaceutical Co., Ltd...announced that its independently developed antibody-drug conjugate YL217 has obtained implicit approval of the new drug clinical trial application (IND) from the U.S. Food and Drug Administration (FDA)."
IND • Oncology
1 to 5
Of
5
Go to page
1